Description
Introduction:
Insulin Glargine is produced by recombinant DNA technology. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginine to the Cterminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4. Small amounts of insulin Glargine are slowly released from microprecipitates giving the drug a long duration of action (up to 24 hours) and no pronounced peak concentration.
Intended Use:
The KRIBIOLISA Insulin Glargine ELISA is used as an analytical tool for quantitative determination of Insulin Glargine in human serum and plasma.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. In the first step, samples and standards are pipetted into microwells. If insulin Glargine is present in the samples or standards, it will form complex with Anti-insulin Glargine antibody, which is pre-coated onto microwells. In the second step, anti-Insulin Glargine HRP conjugate is pipetted and incubated. Free HRP conjugate will be removed by a washing step. In the third step, TMB substrate is added to microwells and color develops proportionally to the amount of Insulin Glargine present in the samples or standards. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!